Analyst Price Target is $9.80
▲ +212.10% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cellectis in the last 3 months. The average price target is $9.80, with a high forecast of $24.00 and a low forecast of $2.00. The average price target represents a 212.10% upside from the last price of $3.14.
Current Consensus is
Hold
The current consensus among 3 investment analysts is to hold stock in Cellectis. This rating has held steady since May 2022, when it changed from a Buy consensus rating.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Read More